卒中后白介素-6、C反应蛋白与血管复发:伴或不伴动脉粥样硬化
结果显示IL-6和hsCRP与卒中后复发风险相关,且不依赖动脉粥样硬化状态。
要点
- IL-6升高与卒中后MACE及复发卒中风险增加相关。
- hsCRP升高与MACE相关,但与复发卒中无显著关联。
- 炎症标志物与复发风险的关联不受动脉粥样硬化状态影响。
核心结论
- IL-6和hsCRP与卒中后复发风险相关,无论患者是否伴有动脉粥样硬化。
研究设计与样本
- 研究为个体参与者数据荟萃分析,纳入11个前瞻性队列(12个国家,1995-2017年)。
主要发现
- 在动脉粥样硬化患者中,IL-6每增加1个loge单位,MACE风险比为1.22(95%CI 1.08-1.37),复发卒中风险比为1.23(95%CI 1.08-1.41)。
- 在动脉粥样硬化患者中,IL-6最高四分位组相比最低四分位组,MACE风险比为2.05(95%CI 1.37-3.08),卒中风险比为1.97(95%CI 1.28-3.05)。
- 在无动脉粥样硬化患者中,IL-6每增加1个loge单位,MACE风险比为1.11(95%CI 1.01-1.23),但与复发卒中的关联无统计学意义(RR 1.08,95%CI 0.98-1.20)。
- hsCRP每增加1个loge单位,在有动脉粥样硬化患者中MACE风险比为1.12(95%CI 1.05-1.21),在无动脉粥样硬化患者中为1.07(95%CI 1.01-1.14);与复发卒中的关联均无统计学意义。
- IL-6与动脉粥样硬化状态对MACE和复发卒中的交互作用P值分别为0.25和0.13;hsCRP的交互作用P值分别为0.28和0.18。
临床怎么用
- 对于卒中后患者,无论是否存在动脉粥样硬化,检测IL-6或hsCRP可能有助于识别炎症相关复发风险较高的个体。
- 研究结果支持将IL-6或hsCRP升高的卒中患者(包括无动脉粥样硬化事件者)纳入抗炎治疗试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uncertainty remains whether inflammation is implicated in poststroke recurrence in patients without atherosclerosis. We evaluated the contribution of atherosclerosis status to the association between inflammatory markers and major adverse cardiovascular events (MACE) poststroke. METHODS: We performed an individual-participant data meta-analysis of 11 prospective cohorts (12 countries, 1995-2017). Studies included patients with ischemic stroke/transient ischemic attack and measured IL (interleukin)-6/hsCRP (high-sensitivity C-reactive protein) postevent. We analyzed the association between IL-6/hsCRP and recurrent stroke/MACE using multivariable Cox regression analyses (conditional logistic regression for 1 study). Analyses were stratified by the presence/absence of atherosclerosis (definition: prior history of coronary disease, peripheral artery disease, or large artery atherosclerotic stroke) and adjusted for cardiovascular risk factors/preventative medication. RESULTS: Overall 10 148 patients (3448 [34.0%] had atherosclerosis) with 21 177 years of follow-up were included (1707 MACE outcomes/1353 recurrent strokes). In patients with atherosclerosis, IL-6 was independently associated with MACE (risk ratio [RR], 1.22 [95% CI, 1.08-1.37]; per logeunit increase) and recurrent stroke (RR, 1.23 [95% CI, 1.08-1.41]). Compared with patients in the bottom quarter, those in the top quarter of IL-6 levels had double the risk of MACE (RR, 2.05 [95% CI, 1.37-3.08]) and stroke (RR, 1.97 [95% CI, 1.28-3.05]). IL-6 was also associated with MACE (RR, 1.11 [95% CI, 1.01-1.23]) but not stroke (RR, 1.08 [95% CI, 0.98-1.20]; per logeunit) in patients without atherosclerosis. However, there was no evidence of statistical interaction between IL-6 levels and atherosclerosis status for either outcome (Pinteraction=0.25 and 0.13 for MACE/recurrent stroke, respectively). hsCRP was associated with MACE in patients with (RR, 1.12 [95% CI, 1.05-1.21]; per logeunit) and without atherosclerosis (RR, 1.07 [95% CI, 1.01-1.14]; Pinteraction=0.28). No association with recurrent stroke was observed for hsCRP with (RR, 1.06 [95% CI, 0.98-1.14]) or without atherosclerosis (RR, 0.97 [95% CI, 0.91-1.04]; Pinteraction=0.18). CONCLUSIONS: IL-6/hsCRP were associated with poststroke recurrence irrespective of atherosclerosis. These data support the inclusion of patients in trials of anti-inflammatory therapies after stroke with elevated IL-6 or hsCRP, including those without prior atherosclerotic events.
引用
- McCabe JJ, Harris K, Walsh C, et al. Interleukin-6, C-Reactive Protein, and Vascular Recurrence After Stroke With and Without Atherosclerosis. Stroke. 2025. PMID: 40677223. doi:10.1161/STROKEAHA.125.052091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。